Brenda Fulmer, a partner in the Mass Tort Unit of Searcy Denney, has filed an individual lawsuit on behalf of an Islamorada businessman against hernia mesh manufacturer Davol, Inc., a division of C.R. Bard. This defective medical product case involves a hernia mesh patch that failed to perform as intended, […]
Progressive Multifocal Leukoencephalopathy (PML) is a devastating diagnosis. It is similar to ALS and other progressive neurological diseases that slowly rob patients of their mobility and functioning. PML is caused by a virus that attacks the central nervous system. Once PML has developed, patients quickly experience a decline in their […]
Pradaxa (also known as Dabigatran Etexilate) is an inactive “parent” drug that relies on the body’s metabolism to eventually manufacture a form of the drug that the body can use as an anti-coagulant, a process that occurs after the drug has been ingested by a patient. Anti-coagulants such as Warfarin […]
In late 2010, the FDA approved the drug called Pradaxa (dabigatran); manufactured by Boehringer Ingelheim. Pradaxa is a blood thinner and is supposed to be prescribed to patients who suffer from the cardiac disorder atrial fibrillation. Atrial Fibrillation is the most common form of abnormal heart rhythm. Patients who suffer […]
Has it simply become all about bean counters and number crunching for some drug companies?
If you can generate over $1.5.8 billion in sales for (5) years, for a drug you know is defective, can you afford to pay the claims that result from people being hurt or killed?
In 2010, the U.S. Food & Drug Administration approved Pradaxa (Dabigatran Etexilate). Pradaxa acts as a blood “thinner” and is promoted to reduce the risk of stroke and blood clots in people with atrial fibrillation. Atrial fibrillation, affecting over two million Americans, occurs when the heart does not beat properly […]
Pradaxa (dabigatran etexilate mesylate), a new oral anticoagulant, achieved Food & Drug Administration (“FDA”) approval on October 19, 2010. One notable advantage of using Pradaxa to replace Warfarin to prevent clot formation is the elimination of INR testing in patients taking Pradaxa. INR is the acronym for International Normalized Ratio, which is used to monitor the effectiveness of anticoagulant such as warfarin.